Eosinophil-mast cell interaction: Mepolizumab leads to a reduction of clinical symptoms and serum tryptase in a patient with eosinophilic asthma and idiopathic mast cell activation

J Allergy Clin Immunol Pract. 2021 Mar;9(3):1393-1395.e1. doi: 10.1016/j.jaip.2020.10.020. Epub 2020 Oct 20.

Authors

Carole Guillet¹, Simona Steinmann², Claudia Lang², Julia-Tatjana Maul², Peter Schmid-Grendelmeier²

Affiliations

¹ Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. Electronic address: carole.guillet@usz.ch.
² Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

PMID: 33096266
DOI: 10.1016/j.jaip.2020.10.020

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma* / drug therapy
Eosinophils*
Humans
Mast Cells
Tryptases

Substances

Antibodies, Monoclonal, Humanized
mepolizumab
Tryptases